Trial: 201909026

A Phase 1b/2a Pilot Randomized Study to Evaluate the Safety and Tolerability of Autologous T-Cells Expressing Enhanced TCRs (T-Cell Receptors) Specific for NY-ESO-1/LAGE-1a (GSK3377794) Alone, or in Combination with Pembrolizumab in HLA-A2+ Participants with NY-ESO-1- or LAGE-1a-Positive Advanced or Recurrent Non-Small Cell Lung Cancer


I/II (Cancer Control)

Principal Investigator

Govindan, Ramaswamy

Disease Site

Lung; Lung Cancer – Non-small Cell

Learn more about this study at: